The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.
David F. McDermott
No relevant relationships to disclose
Charles G. Drake
No relevant relationships to disclose
Mario Sznol
No relevant relationships to disclose
Jeffrey Alan Sosman
No relevant relationships to disclose
David C. Smith
No relevant relationships to disclose
John D. Powderly
No relevant relationships to disclose
David M. Feltquate
No relevant relationships to disclose
Georgia Kollia
No relevant relationships to disclose
Ashok Kumar Gupta
No relevant relationships to disclose
Jon Wigginton
No relevant relationships to disclose